Sarepta Therapeutics Inc. (NASDAQ:SRPT) Given Average Rating of “Buy” by Brokerages
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) have been assigned a consensus recommendation of “Buy” from the twenty research firms that are covering the stock. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $55.02.
A number of research firms have recently weighed in on SRPT. Oppenheimer Holdings Inc. increased their target price on shares of Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday. JMP Securities raised shares of Sarepta Therapeutics to an “outperform” rating and increased their price target for the stock from $10.00 to $60.00 in a research note on Monday. Wedbush reissued an “outperform” rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday. SunTrust Banks Inc. raised shares of Sarepta Therapeutics to a “reduce” rating and increased their price target for the stock from $4.00 to $48.00 in a research note on Tuesday. Finally, WBB Securities reissued a “strong-buy” rating and issued a $60.00 price target (up from $40.00) on shares of Sarepta Therapeutics in a research note on Tuesday.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.906% during trading on Wednesday, hitting $55.225. The stock had a trading volume of 5,934,892 shares. The stock has a 50 day moving average of $28.17 and a 200 day moving average of $21.37. The firm’s market cap is $2.65 billion. Sarepta Therapeutics has a 52-week low of $8.00 and a 52-week high of $58.87.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sarepta-therapeutics-inc-nasdaqsrpt-given-average-rating-of-buy-by-brokerages.html
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the firm posted ($0.87) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($4.98) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 24,557 shares of Sarepta Therapeutics stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares in the company, valued at approximately $2,309,490. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Vanguard Group Inc. boosted its position in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares in the last quarter. State Street Corp boosted its position in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at $13,506,000. Institutional investors and hedge funds own 72.09% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.